Targeting the endogenous cannabinoid system to treat neuropathic pain.
about
Excess cerebral TNF causing glutamate excitotoxicity rationalizes treatment of neurodegenerative diseases and neurogenic pain by anti-TNF agentsTRP channel cannabinoid receptors in skin sensation, homeostasis, and inflammationWhat failed BIA 10-2474 Phase I clinical trial? Global speculations and recommendations for future Phase I trials.Fatty acid amide hydrolase-morphine interaction influences ventilatory response to hypercapnia and postoperative opioid outcomes in children.What failed BIA 10–2474 Phase I clinical trial? Global speculations and recommendations for future Phase I trials.
P2860
Targeting the endogenous cannabinoid system to treat neuropathic pain.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Targeting the endogenous cannabinoid system to treat neuropathic pain.
@en
type
label
Targeting the endogenous cannabinoid system to treat neuropathic pain.
@en
prefLabel
Targeting the endogenous cannabinoid system to treat neuropathic pain.
@en
P2860
P356
P1476
Targeting the endogenous cannabinoid system to treat neuropathic pain.
@en
P2093
Benjamin K Lau
Christopher W Vaughan
P2860
P356
10.3389/FPHAR.2014.00028
P577
2014-03-03T00:00:00Z